A Next Generation Immune therapy
The most advanced ENPP1 inhibitor program in the Clinic
Vizenpistat (SR-8541A) is A best-in-class innate immune checkpoint inhibitor — now in active clinical trials across multiple cancer indications, with a strong and well-characterized safety profile and promising early clinical data
$20M+
Non-dilutive grants & awards
~50%
Of all cancers suppress innate immunity
0
Serious drug-related side effects observed at any dose level tested
#1
Ranked ENPP1 inhibitor program by clinical advancement
Our Approach
A new frontier in immuno-oncology
Half of all cancers silence innate immunity — the immune system's first line of defense. Checkpoint inhibitors targeting the adaptive immune system have transformed oncology, but for the millions of patients whose tumors shut down innate immunity, they aren't enough.
Vizenpistat changes that equation. By blocking ENPP1 — the only known checkpoint in innate immunity — Vizenpistat reactivates the cGAS-STING pathway and enables the full immune system to fight back. Because innate immune suppression occurs across a wide range of tumor types, Vizenpistat has the potential to benefit patients far beyond any single indication.
Broad Applicability
Targeting cancers across multiple indications
Active · Phase 1b/2
Metastatic MSS colorectal cancer
In combination with botensilimab + balstilimab. Funded by CPRIT grant + NCI SBIR Bridge award
Active · Phase 1
Advanced solid tumors
Single-agent dose escalation safety assessment. 8 dose levels cleared, zero DLTs.
Planned expansion
Anal cancer
High unmet need, strong preclinical rationale.
Planned expansion
Metastatic prostate cancer
High ENPP1 expression, compelling combination rationale.
Planned expansion
Osteosarcoma
Pediatric/young adult bone cancer with limited approved options & strong preclinical rationale.
Combination platform
Radiation, chemo & cancer vaccines
Preclinical synergy with Pluvicto and other modalities.
Validated by $20M+ in non-dilutive funding
Stingray has secured over $20M in non-dilutive grants and awards, including a $14M CPRIT grant a $2M Direct-to-Phase-2 NCI SBIR Award, and a $4M NCI SBIR Bridge Award — further validating the science and de-risking the path to the clinic.
